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Abstract 
 
Background:  
Many patients presented to the causality with upper gastrointestinal bleeding, which is a serious 
condition associated with significant morbidity and mortality especially in elderly patients and 
those with coexisting medical diseases. 
Objectives:  
To assess the general use of NSAIDs and their relation to upper gastrointestinal bleeding. 
Methods:  
Cross sectional study on patients who were referred for endoscopy for upper gastrointestinal 
bleeding in Sulaimany Teaching Hospital during the period from January to December 2016. All 
of them had been exposed to full history taking regarding age, gender, smoking, alcohol and 
medication used in addition to thorough physical examination and upper gastrointestinal 
endoscopic examination with biopsy when indicated. 
Results:   
This study enrolled 100 patients with upper GIT bleeding and   showed that 48% of those with 
upper GIT bleeding were using NSAIDs, with male to female ratio of approximately 2:1, and 37 
patients (77.1%) of those who were taken NSAIDs, did not use PPI concomitantly The study also 
revealed that elderly patients taking NSAIDs were at higher risk of developing upper GIT 
bleeding. 
CONCLUSIONS: 
Elderly patients who were taken NSAIDs associated with significant upper GIT bleeding, and 
their uses were without prophylactic PPI cover in high risk individuals. 
 
Introduction: 
  
      Approximately 50 non-steroidal anti-inflammatory drugs (NSAIDs) are in use throughout the 
world, the oldest and best known is aspirin. NSAIDs are popular because of their versatile 
effectiveness as analgesics, antipyretics, and (by definition) as anti-inflammatory agents
 (14).
 
Aspirin is also widely used as an anti-thrombotic agent. Unfortunately, aspirin and most other 
NSAIDs can injure the gastric and duodenal mucosa, with considerable morbidity and mortality
 
(14)
 
  UGI bleeding commonly presents with hematemesis (vomiting of blood or coffee-ground like 
material) and/or melena (black, tarry stools). A nasogastric tube lavage which yields blood or 
coffee-ground like material confirms this clinical diagnosis. However, lavage may not be 
positive if bleeding has ceased or arises beyond a closed pylorus. 
        Gastroduodenal ulcer disease remains a common cause of UGI bleeding   
(1)  
There are four 
major risk factors for bleeding peptic ulcers 
(2, 3)
 Helicobacter pylori infection ,  nonsteroidal 
antiinflammatory drugs (NSAIDs) stress ,gastric acid .Reduction or elimination of these risk 
factors reduces ulcer recurrence and rebleeding rates
(4,5,6,7 ) , 
 NSAIDs are a common cause of 
  
 
gastrointestinal ulceration
(8,9,10,11) . 
However, all patients with a prior history of bleeding ulcer 
disease are at increased risk for recurrent ulcer and complications 
(12, 13, and 14). 
 
NSAIDs also have been implicated as an important factor for non-healing ulcers 
(15). 
 
 Endoscopy is the preferred investigative procedure for upper gastrointestinal bleeding 
because of its accuracy, low rate of complications and potential for therapeutic    intervention
 
(16).
 
Pathology — Acute hemorrhagic and erosive gastropathy appears as multiple petechial 
hemorrhages and small red or black erosions on endoscopy 
(17, 18).
 Stress-related lesions 
(Curling's ulcers) usually appear in the fundus near the gastroesophageal junction and spread 
distally, but remain confined to the fundus and body 
(18).
 In contrast, gastropathy due to 
NSAIDs and alcohol involves the entire stomach from the start, although it may be most 
evident in the antrum 
(18)
 
 
The healthy gastric and duodenal mucosae constitutively use COX- to produce its mucosal 
protective PGs 
(18) 
Many NSAIDs block COX-1 and COX-2 more or less equally (i.e. are 
non-selective) and thus impair gastric  PG production at low (<1µM) 
concentrations  ,examples include aspirin, indomethacin, ibuprofen, and naproxen. Most 
drugs that spare COX-1 and selectively inhibit COX-2 have less suppressive effects on 
gastric PG synthesis, examples include celecoxib and etodolac. As a result, selective 
inhibitors of COX-2, and also COX–3 inhibitors such as acetaminophen, preserve PG-
mediated GI mucosal protection (
19, 20, and 21)
 .However, COX-2 selective inhibitors can lose 
their specificity for COX-2 at high doses and have the potential to also block COX-1 in the 
stomach and duodenum and cause damage.                                                                              
American College of Gastroenterology recommendations — A committee appointed by the 
American College of Gastroenterology has critically reviewed the data regarding the risk 
factors for NSAID toxicity, and identified the five most important variables that place 
patients at risk for NSAID-related gastrointestinal complications   
(22).
  
1- Prior history of an adverse GI event (ulcer, hemorrhage) increases risk four to fivefold . 
2- Age >60 increases risk five- to sixfold . 
3- High  dosage of a NSAID increases risk 10-fold . 
4-  Concurrent use of glucocorticoids increases risk four to fivefold. 
5-   Concurrent use of anticoagulants increases risk 10- to 15-fold . 
  Patients with several risk factors are at highest risk for NSAID-induced GI toxicity (up to 9 
percent after six months) 
(23,24) 
, Assessment of these risk factors is recommended for 
identifying patients who should be considered for prophylaxis if it is felt that an NSAID must 
be given. 
Aim of the study: 
 
1. To determine the overall causes of upper GIT bleeding. 
2. To determine the frequency of NSAIDs induced upper GIT bleeding. 
3. To assess local practice in using prophylaxis against   NSAIDs induced upper GIT 
bleeding. 
Patients and methods:  
       This study is a cross sectional study. One hundred patients with upper GIT bleeding had 
been included in this study. They were randomly selected from those who were referred for GIT 
centre at Sulaimany Teaching Hospital during the period from January to December 2016. All of 
them had been exposed to full history taking regarding age, gender, smoking, alcohol intake and 
  
 
medication used, in addition to thorough physical examination and upper gastrointestinal 
endoscopy with biopsy when indicated. 
      We excluded those patients with history of upper GIT bleeding with no endoscopic evidence 
of bleeding.  
All of the collected data had been analyzed using Microsoft Excel and Statistical Package for 
Social Sciences (SPSS) software. The data had been tabulated in form of frequency distribution 
tables and graphs. Student’s t-test and Chi-square test had been used for testing the level of 
significant association or difference between different quantitative and qualitative groups, 
respectively. A value of less than 0.05 had been selected as the P value required to determine the 
significant association or difference.   
 Results:  
    This study enrolled 100 patients with upper GIT bleeding. The sample included 66 male (66% 
of the sample) and 34 female patients (34% of the sample). The mean age of the patients was 
49.33   14.9 year old (range: 20-80year old). The mean age of male patients was 50.26  13.7 
year old (range: 23-80year old) and the mean age of the female patients was 47.5 17.1 year old 
(range 20-70 year old). Twenty nine patients (29% of the sample) were 60 years or older. 49 
male patients were younger than 60 years (74.3% of male patients) compared to 22   females 
patients (64.7% of female patients) were within the same age group.  
Table- 1 shows age and gender distribution of the sample.  
  
Age group Male Female  M:F ratio 
No.  % No.  % 
20- 39 year old 17 25.8% 12 35.3% 1.4:1 
40-59 year old 32 48.5% 10 29.4% 3.2:1 
 60 17 25.8% 12 35.3% 1.4:1 
total 66 100.0% 34 100.0% 1.9:1 
 
 
Table - 2: patient’s distribution according to their age and history of NSAID use 
Age group Use NSAIDs Not use NSAIDs 
No. % No. % 
20-39 year- old 9 31.0% 20 69.0% 
40-59year old 15 35.7% 27 64.3% 
≥60 year old 24 82.8% 5 17.2% 
Total(n=100) 48 48.0% 52 52.2% 
mean± SD 53.63± 16.5 45.37±12.2 
Statistical analysis Calculated t = 2.84, p value = 0.01 
 
 it can be seen clearly from table -2 that total number of patients   taken NSAIDs were 48, with 
mean± SD 53.63± 16.5, and total number of patients who did not taken NSAIDs are52 with 
mean± SD 45.37±12.2 which represent statically significant association between NSAIDs and 
upper GIT bleeding with calculated t =2.84 and p value 0.01, it can also be seen that 82.8% of 
those aged above 60 year old were taken NSAIDs. 
  
 
 
Graph 1: frequency of gastrointestinal irritant agents. 
It can be seen clearly from the graph 1 that approximately half of those with upper GIT bleeding 
were taking NSAID, while steroids 3% of the sample, alcohol 3% and 16 % of patients were 
smokers.  
 
 
 Graph 2: frequency of different NSAIDs usage 
 Graph 2: demonstrate aspirin is the most frequently used drugs among the NSAID 
which represent 64.4%, while the selective NSAID usage is only 6.25% from the total usage of 
NSAID. It had been shown that there was a significant association between the use of NSAIDs in 
all of their types and the development of upper GIT bleeding (X
2 
= 5.6, p value = 0.001). On the 
other hand no statistically significant association had been observed between use of COX-2 
inhibitors and the development of upper GIT bleeding (X
2
 = 1.43, p value > 0.05).  
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TABLE- 3: patient’s distribution according to their history of NSAIDs and PPI use. 
 Use  NSAIDs 
No. % 
Use PPI 11 22.9% 
Did not use PPI 37 77.1% 
Total 48 100% 
 
We can see from table 3 that the majority of patients who use NSAIDs (77.1%) do not use PPI 
concomitantly, compared to (22.9%) who were using PPI. 
 
 
Table 4: Patients’ distribution according to the endoscopic finding and their history of NSAIDs 
use 
  use NSAIDs Did not use NSAIDs 
No. % No. % 
 Duodenal ulcer 18 34.6% 34 65.3% 
 Erosive gastritis 13 61.9% 8 38.1% 
Gastric ulcer 10 76.9% 3 23.1% 
Oesophagitis 3 60% 2 40% 
Oesophageal varices 1 33.3% 2 66.7% 
Gastric malignancy 2 66.7% 1 33.3% 
Mallory Weiss syndrome 0 0% 2 100% 
Gastric arteriovenous malformation 1 100% 0 0% 
 
  Discussion: 
Acute upper GIT bleeding is a common emergency with important implications for health care 
costs worldwide. Negative outcomes include rebleeding and death, and many of the deaths are 
associated with decompensation of coexisting medical condition precipitated by acute bleeding 
events
 (25)
. In a study from one large health maintenance organization, the annual incidence of 
hospitalization for acute upper GIT bleeding was 102 per 100 000; the incidence was twice as 
common in males as in females and increased with age
 (26)
. Similar findings were observed in this 
study which indicated that overall male to female ratio in all age groups was 1.9:1. Furthermore, 
this phenomenon of higher frequency of upper GIT bleeding was most prominent and evident 
among those whose age ranged between 40 and 59 year-old with a frequency of upper GIT 
bleeding among male patients 3 times its frequency among female patients. The M: F ratio 
showed some decline among those aging 60 years or older, with M: F ratio of about 1.4:1. 
Examining the data collected from this study showed that in this age group, female patients were 
more frequently using NSAIDs drugs for different reasons and with the possible taking of drugs 
with more toxic effects on the gastrointestinal tract. In addition, many other studies showed that 
the impact of NSAIDs on the risk of upper GIT bleeding was greater in women than in men
 (27, 28, 
and 29)
.  
Age had been considered as one of five most important risk factors for gastroduodenal toxicity 
from NSAIDs according to the committee appointed by the American College of 
Gastroenterology
 (30)
. Similarly, this study showed that elderly patients taking NSAIDs were at 
  
 
higher risk of developing upper GIT bleeding, as 24 out of 29 patients with an age of 60 years or 
older (82.8%) were taking NSAIDs, In contrast, only 9 out of 29 patients (31%) whose age was 
20-39 year-old were taking NSAIDs indicating that the effect of other risk factors for upper GIT 
bleeding had stronger effect in comparison to the effect of NSAIDs on the frequency of upper 
GIT bleeding among young patients.  
Regarding the history of NSAIDs use including the use of aspirin in all of its recommended 
doses, many studies with different designs reached the conclusion of considering the use of 
NSAIDs as a major risk factor in the development of upper GIT bleeding which is the main 
cause of morbidity and mortality related to NSAIDs use
(31,32)
 In the United States cohort of 
rheumatoid arthritis patients alone, it has been estimated that GI toxicity related to NSAIDs use 
accounts for at least 2600 deaths annually
(33)
. This study had shown that 48% of those with upper 
GIT bleeding were using NSAIDs, making the use of NSAIDs the most frequent risk factors for 
developing upper GI bleeding in the sample enrolled in this study. Lim et al (2005) indicated that 
over 25% of those with significant upper GIT bleeding were using NSAIDs including COX2 
inhibitors
 (31)
. The relatively higher frequency of NSAIDs use among patients enrolled in our 
study (48% in our study versus 25% in Lim’s study) can be attributed to the current trends in our 
community where drugs are available without proper prescription by an authorized physician; 
this makes a lot of NSAIDs as an over the shelf medicine with more frequent use as an analgesic.     
This study indicated that different types of NSAIDs had different frequency of usage in patients 
with upper GIT bleeding, with aspirin as the most frequently used drug (64.6% of the sample). 
Other NSAIDs were observed much less frequently including ibuprofen, diclofenac (Voltarin®), 
indomethacin (Indocid®) and meloxicam ( mobic®), which had been used by 16.7%, 12.8%, 
8.3% and 6.25% of patients, respectively. On reviewing the results of similar studies , the risk of 
gastrointestinal complications was highest with indomethacin and putting ibuprofen at the 
bottom of the list
(34)
. Another potentially important finding that can be derived from this study is 
that cox2 inhibitors are the least frequent risk factor for upper GI bleeding in our sample (6.25% 
of the sample).   This finding is similar to the finding of two large trials that studied the effect of 
cox2 inhibitors to reduce the gastrointestinal complications. The first trial is the CLASS study 
which involved 8059 patients and found that over the initial six months of therapy, cox2 
inhibitors were associated with significantly fewer symptomatic ulcers and ulcer complications 
than ibuprofen or diclofenac 
(35)
. A second trial (the SUCCESS-I study) included a total of 13, 
274 patients with osteoarthritis from 39 countries and found that there was a reduction in 
gastrointestinal complications only in patients not taking concomitant aspirin i.e. cox2 inhibitors 
only
 (36)
.  
The cornerstone in approaching the problem of NSAIDs induced gastrointestinal toxicity is the 
primary prevention of such a catastrophic adverse effect aiming to reduce the associated high 
mortality and morbidity
 (32)
. Proton pump inhibitors (PPIs) are useful for the prevention of 
NSAIDs induced ulcers
 (37-40)
. In an illustrative study, the combined incidence of gastric and 
duodenal ulcers detected endoscopically was reduced in patients who were also treated with 20 
mg omeprazole per day (3.6% versus 16.5% with placebo at 6 months)
 (40)
. Unfortunately, our 
study only 11 out of 48 patients using NSAIDs (22.9%) were taking PPIs for the prevention of 
NSAIDs induced GIT bleeding. This means that the remaining 37 patients (77.1%) had been 
deprived from the protecting effect of PPIs use despite their history of NSAIDs intake. 
This study revealed that NSAIDs use was more frequently associated with gastric mucosal injury. 
Twenty three out of 34 patients (67.6%), diagnosed endoscopically as having a gastric mucosal 
injury in  the form of either erosive gastritis (13 patients) or gastric ulcer (10 patients), were 
  
 
using NSAIDs. This higher frequency of gastric mucosal injury in association with NSAIDs use 
in comparison to less frequent injuries to other parts of GI tract, can be related to the fact that 
gastric mucosa, not the duodenal or esophageal mucosa, is dependent on COX-1 (which would 
be inhibited by NSAIDs) to generate mucosal-protective prostaglandins. This protective 
mechanism can be inhibited by a very low dose of aspirin or other NSAIDs. Cryer et al found 
that aspirin doses as low as 10 mg/day can inhibit gastric prostaglandin generation considerably 
and can damage the stomach
 (41)
. In contrast, some studies showed that aspirin doses as low as 
325 mg/day every other day increase the risk of duodenal ulcer
 (42)
. Although the risk of gastric 
mucosal injury is increased with increasing dose of NSAIDs depending on the finding of several 
epidemiological and placebo controlled studies
 (43-45)
, but lower doses of NSAIDs are required to 
initiate gastric mucosal injury compared to the high doses required for creating the same degree 
of injury in the mucosa of other parts of GIT. 
 CONCLUSIONS: 
 Elderly patients who were taken NSAIDs associated with significant upper GIT bleeding, and 
their uses were without prophylactic PPI cover in high risk individuals. 
Recommendation: 
1.  We have to increase public and physician awareness of NSAIDs side 
effects ,and limit its usage whenever possible  
2. To cover NDAIDs usage with prophylactic PPI in high risk groups 
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